263 related articles for article (PubMed ID: 33222272)
1. Similarly low risk of hepatocellular carcinoma after either spontaneous or nucleos(t)ide analogue-induced hepatitis B surface antigen loss.
Yip TC; Wong VW; Tse YK; Liang LY; Hui VW; Zhang X; Li GL; Lui GC; Chan HL; Wong GL
Aliment Pharmacol Ther; 2021 Jan; 53(2):321-331. PubMed ID: 33222272
[TBL] [Abstract][Full Text] [Related]
2. HBsAg seroclearance further reduces hepatocellular carcinoma risk after complete viral suppression with nucleos(t)ide analogues.
Yip TC; Wong GL; Chan HL; Tse YK; Lam KL; Lui GC; Wong VW
J Hepatol; 2019 Mar; 70(3):361-370. PubMed ID: 30367899
[TBL] [Abstract][Full Text] [Related]
3. Impact of age and gender on risk of hepatocellular carcinoma after hepatitis B surface antigen seroclearance.
Yip TC; Chan HL; Wong VW; Tse YK; Lam KL; Wong GL
J Hepatol; 2017 Nov; 67(5):902-908. PubMed ID: 28652084
[TBL] [Abstract][Full Text] [Related]
4. Risk of hepatic decompensation but not hepatocellular carcinoma decreases over time in patients with hepatitis B surface antigen loss.
Yip TC; Wong VW; Lai MS; Lai JC; Hui VW; Liang LY; Tse YK; Chan HL; Wong GL
J Hepatol; 2023 Mar; 78(3):524-533. PubMed ID: 36463985
[TBL] [Abstract][Full Text] [Related]
5. Cumulative incidence of hepatocellular carcinoma and hepatitis B surface antigen Seroclearance after Nucleos(t) ide analogue-induced hepatitis B e antigen Seroclearance.
Lee HW; Lee JI; Kim S; Kim S; Chang HY; Lee KS
BMC Gastroenterol; 2020 Apr; 20(1):113. PubMed ID: 32305059
[TBL] [Abstract][Full Text] [Related]
6. Comparison of Long-Term Clinical Outcomes Between Spontaneous and Therapy-Induced HBsAg Seroclearance.
Choi J; Yoo S; Lim YS
Hepatology; 2021 Jun; 73(6):2155-2166. PubMed ID: 33131063
[TBL] [Abstract][Full Text] [Related]
7. Discontinuation of nucleos(t)ide analogues is not associated with a higher risk of HBsAg seroreversion after antiviral-induced HBsAg seroclearance: a nationwide multicentre study.
Kim MA; Kim SU; Sinn DH; Jang JW; Lim YS; Ahn SH; Shim JJ; Seo YS; Baek YH; Kim SG; Kim YS; Kim JH; Choe WH; Yim HJ; Lee HW; Kwon JH; Lee SW; Jang JY; Kim HY; Park Y; Kim GA; Yang H; Lee HA; Koh M; Lee YS; Kim M; Chang Y; Kim YJ; Yoon JH; Zoulim F; Lee JH
Gut; 2020 Dec; 69(12):2214-2222. PubMed ID: 32209606
[TBL] [Abstract][Full Text] [Related]
8. Clinical outcomes after spontaneous and nucleos(t)ide analogue-treated HBsAg seroclearance in chronic HBV infection.
Chen YC; Jeng WJ; Chien RN; Chu CM; Liaw YF
Aliment Pharmacol Ther; 2016 Jun; 43(12):1311-8. PubMed ID: 27072504
[TBL] [Abstract][Full Text] [Related]
9. HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durability.
Kim GA; Lim YS; An J; Lee D; Shim JH; Kim KM; Lee HC; Chung YH; Lee YS; Suh DJ
Gut; 2014 Aug; 63(8):1325-32. PubMed ID: 24162593
[TBL] [Abstract][Full Text] [Related]
10. The safety of stopping nucleos(t)ide analogue treatment in patients with HBeAg-negative chronic hepatitis B.
Wong GL; Chan HL; Yuen BW; Tse YK; Luk HW; Yip TC; Hui VW; Liang LY; Lee HW; Lui GC; Wong VW
Liver Int; 2020 Mar; 40(3):549-557. PubMed ID: 31845462
[TBL] [Abstract][Full Text] [Related]
11. Risk and Risk Score Performance of Hepatocellular Carcinoma Development in Patients With Hepatitis B Surface Antigen Seroclearance.
Park Y; Lee JH; Sinn DH; Park JY; Kim MA; Kim YJ; Yoon JH; Kim DY; Ahn SH; Kang W; Gwak GY; Paik YH; Choi MS; Lee JH; Koh KC; Paik SW
Clin Transl Gastroenterol; 2021 Jan; 12(1):e00290. PubMed ID: 33433118
[TBL] [Abstract][Full Text] [Related]
12. Long-term outcomes and predictive scores for hepatocellular carcinoma and hepatitis B surface antigen seroclearance after hepatitis B e-antigen seroclearance.
Fung J; Cheung KS; Wong DK; Mak LY; To WP; Seto WK; Lai CL; Yuen MF
Hepatology; 2018 Aug; 68(2):462-472. PubMed ID: 29534307
[TBL] [Abstract][Full Text] [Related]
13. Effects of Diabetes and Glycemic Control on Risk of Hepatocellular Carcinoma After Seroclearance of Hepatitis B Surface Antigen.
Cheuk-Fung Yip T; Wai-Sun Wong V; Lik-Yuen Chan H; Tse YK; Pik-Shan Kong A; Long-Yan Lam K; Chung-Yan Lui G; Lai-Hung Wong G
Clin Gastroenterol Hepatol; 2018 May; 16(5):765-773.e2. PubMed ID: 29246694
[TBL] [Abstract][Full Text] [Related]
14. Systematic review of risk factors of hepatocellular carcinoma after hepatitis B surface antigen seroclearance.
Kuang XJ; Jia RR; Huo RR; Yu JJ; Wang JJ; Xiang BD; Li LQ; Peng Z; Zhong JH
J Viral Hepat; 2018 Sep; 25(9):1026-1037. PubMed ID: 29624821
[TBL] [Abstract][Full Text] [Related]
15. Association Between Fatty Liver and Cirrhosis, Hepatocellular Carcinoma, and Hepatitis B Surface Antigen Seroclearance in Chronic Hepatitis B.
Li J; Yang HI; Yeh ML; Le MH; Le AK; Yeo YH; Dai CY; Barnett S; Zhang JQ; Huang JF; Trinh HN; Wong C; Wong C; Hoang JK; Cheung R; Yu ML; Nguyen MH
J Infect Dis; 2021 Jul; 224(2):294-302. PubMed ID: 33249474
[TBL] [Abstract][Full Text] [Related]
16. A risk prediction model for hepatocellular carcinoma after hepatitis B surface antigen seroclearance.
Yang H; Bae SH; Nam H; Lee HL; Lee SW; Yoo SH; Song MJ; Kwon JH; Nam SW; Choi JY; Yoon SK; Jang JW
J Hepatol; 2022 Sep; 77(3):632-641. PubMed ID: 35398462
[TBL] [Abstract][Full Text] [Related]
17. Systematic review with meta-analysis: development of hepatocellular carcinoma in chronic hepatitis B patients with hepatitis B surface antigen seroclearance.
Liu F; Wang XW; Chen L; Hu P; Ren H; Hu HD
Aliment Pharmacol Ther; 2016 Jun; 43(12):1253-61. PubMed ID: 27117732
[TBL] [Abstract][Full Text] [Related]
18. CAMP-B score predicts the risk of hepatocellular carcinoma in patients with chronic hepatitis B after HBsAg seroclearance.
Lee HW; Yip TC; Wong VW; Lim YS; Chan HL; Ahn SH; Wong GL; Choi J
Aliment Pharmacol Ther; 2024 May; 59(10):1223-1235. PubMed ID: 38425096
[TBL] [Abstract][Full Text] [Related]
19. The suppressive effect of nucleos(t)ide analogue treatment on the incidence of hepatocellular carcinoma in chronic hepatitis B patients.
Hiramatsu N; Yamada R; Takehara T
J Gastroenterol Hepatol; 2016 Mar; 31(3):546-52. PubMed ID: 26574149
[TBL] [Abstract][Full Text] [Related]
20. Kinetics of serum O-glycosylated M-hepatitis B surface antigen with hepatocellular carcinoma history and nucleos(t)ide analogue therapy in hepatitis B patients.
Okumura T; Joshita S; Iwadare T; Wakabayashi SI; Kobayashi H; Yamashita Y; Sugiura A; Kimura T; Umemura T
J Viral Hepat; 2023 Sep; 30(9):731-739. PubMed ID: 37363934
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
